SCHEMBL9982240

SCHEMBL9982240

COc1cccc(-c2cc(F)ccc2C)n1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.51
HSP90AA1 P07900 12/20 0.48
HSP90AB1 P08238 2/20 0.48
TRAP1 Q12931 1/20 0.48
CTSA P10619 1/20 0.41
BTK Q06187 1/20 0.40
AR P10275 1/20 0.40
PDE2A O00408 1/20 0.39
PDE6D O43924 1/20 0.39
PDE6A P16499 1/20 0.39
PDE6G P18545 1/20 0.39
PDE6B P35913 1/20 0.39
PDE6C P51160 1/20 0.39
PDE3B Q13370 1/20 0.39
PDE6H Q13956 1/20 0.39
PDE3A Q14432 1/20 0.39
PDE10A Q9Y233 1/20 0.39
AGPAT2 O15120 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10304939 0.88 PDE2A (0.47) ABL1HSP90AA1HSP90AB1TRAP1CTSA
SCHEMBL10305012 0.84 HSP90AA1 (0.46) ABL1HSP90AA1HSP90AB1BTKAR
SCHEMBL10304970 0.84 HSP90AA1 (0.50) ABL1HSP90AA1HSP90AB1TRAP1CTSA
SCHEMBL13745269 0.83 HSP90AA1 (0.50) ABL1HSP90AA1HSP90AB1TRAP1BTK
SCHEMBL10304967 0.83 HSP90AA1 (0.47) ABL1HSP90AA1HSP90AB1BTK
SCHEMBL10305102 0.80 HSP90AA1 (0.48) ABL1HSP90AA1HSP90AB1PDE2APDE10A
SCHEMBL19153108 0.80 HSP90AA1 (0.47) ABL1HSP90AA1HSP90AB1TRAP1BTK
SCHEMBL10305014 0.79 FFAR1 (0.39) HSP90AA1HSP90AB1TRAP1BTK
SCHEMBL10304963 0.78 PDE2A (0.48) HSP90AA1HSP90AB1BTKPDE2APDE6D
SCHEMBL10305037 0.78 BTK (0.42) HSP90AA1HSP90AB1BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2252595-B1 OXIM DERIVATIVES AS HSP90 INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2014-03-26 EP disclosed
US-20120264770-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-18 US disclosed
US-20120172321-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-05 US disclosed
US-8211885-B2 Cyclic indole-3-carboxamides, their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2012-07-03 US disclosed
US-20090305998-A1 HSP90 INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090305998-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ABL1 177/4885HSP90AA1 2/4885HSP90AB1 1/4885
US-20120264770-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ABL1 177/4885HSP90AA1 2/4885HSP90AB1 1/4885
US-20120172321-A1 HSP90 INHIBITORS HSP90AB1, HSP90AA1, HSP90B1 ABL1 177/4885HSP90AA1 2/4885HSP90AB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.